This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Medicenna to Present at Investor Conference
Business investor conference

Medicenna to Present at Investor Conference

Analysis based on 6 articles · First reported Apr 14, 2026 · Last updated Apr 14, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement by Medicenna Therapeutics to present at an investor conference with new preclinical data could positively impact its stock price by increasing investor awareness and confidence. The event provides a platform for Medicenna Therapeutics to attract new investors and potentially secure funding for its drug development programs.

Biotechnology Pharmaceuticals
Event Summary

Medicenna Therapeutics Corp. announced that its President and CEO, Fahar Merchant, will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. During the presentation, Medicenna Therapeutics will provide a corporate update and share the latest preclinical data for its MDNA113 program, which was previously presented at the 2026 Annual Meeting of the American Association for Cancer Research. The conference aims to connect U.S., Canadian, and international investors with Canadian healthcare companies. Medicenna Therapeutics is a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune diseases, with products like MDNA11 and bizaxofusp (MDNA55) in its pipeline, the latter having received FastTrack and Orphan Drug status from the United States — Food and Drug Administration and European Union — European Medicines Agency.

Entities Involved
stock
Medicenna Therapeutics
Medicenna Therapeutics will present a corporate update and preclinical data for MDNA113 at the 2026 Bloom Burton & Co. Healthcare Investor Conference, potentially increasing investor interest.
Importance 100.0 Sentiment 20.0
per
Fahar Merchant
Fahar Merchant, President and CEO of Medicenna Therapeutics, will present at the conference, representing the company and its developments.
Importance 80.0 Sentiment 20.0
ngo
American Association for Cancer Research
Medicenna Therapeutics will present preclinical data from the 2026 Annual Meeting of the American Association for Cancer Research, indicating the source of their latest scientific findings.
Importance 30.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
Importance 0.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
cnt
Canada
Importance 0.0 Sentiment 0.0
Relationships
European Union — European Medicines Agency related ↔ United States — Food and Drug Administration
European Union — European Medicines Agency related ↔ United States
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ Canada
United States strained-ally ↔ Canada The United States has severely strained its historically close relationship with Canada by imposing sweeping tariffs and
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.